Synektik (STU:A2P) Research & Development: €0.7 Mil (TTM As of Mar. 2026)


STU:A2P Synektik SA STU:A2P
85 GF Score
Price €73.85
GF Value €51.60
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Synektik Research & Development?

Synektik STU:A2P +0.89% 85 Research & Development is €0.7 Mil as of Mar. 2026. GuruFocus rates STU:A2P with a GF Score™ of 85/100 and a GF Value™ of €51.60 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Synektik's Research & Development for the three months ended in Mar. 2026 was €0.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.7 Mil.

Synektik  (STU:A2P) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Synektik Research & Development Related Terms

Synektik Research & Development Historical Data

* Premium members only.

The historical data trend for Synektik's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synektik Research & Development Chart

Synektik Annual Data
Trend Dec14 Dec15 Dec16 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.22 1.43 2.38 3.72 0.79

Synektik Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.25 0.14 0.17 0.19
STU:A2P
85GF Score
Synektik SA STU:A2P
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synektik Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.7 Mil mean?
Synektik (STU:A2P) has a Research & Development of €0.7 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Synektik and its competitors.
Is Synektik's Research & Development too high?
Synektik's current Research & Development is €0.7 Mil. Overall, Synektik has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's Research & Development compare to ABT and SYK?
Synektik's Research & Development of €0.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Synektik and its competitors. Synektik's current Research & Development is €0.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (STU:A2P) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.60, compared to a current price of €73.85 — trading 43.1% above its estimated fair value. The current Research & Development is €0.7 Mil. Synektik's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Synektik (STU:A2P), the current Research & Development is €0.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synektik (STU:A2P) Overvalued in 2026?

Based on GuruFocus' analysis, Synektik stock appears to be overvalued. The current stock price of €73.85 is trading 43.1% above its estimated GF Value™ of €51.60. GuruFocus considers Synektik to be Significantly Overvalued.

Key valuation signals for STU:A2P:

  • Research & Development: €0.7 Mil
  • GF Value™: €51.60 vs. price of €73.85 (43.1% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the STU:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synektik Business Description

Other Exchanges SNT:PolandA2P:Germany
Address Aleja Wincentego Witosa 31, Warsaw, POL, 00-710
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
85GF Score

Get the complete analysis for STU:A2P

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.85
Price
€51.60
GF Value